Another month, another gliflozin filing in Japan
This article was originally published in Scrip
Approval submissions for Japan's next class of diabetes drugs, the "gliflozin" sodium-glucose co-transporter 2 (SGLT2) inhibitors, continue to come thick and fast, with Sanofi and Kowa the latest to enter the highly competitive fray with tofogliflozin (CSG452).
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?